MNOV (MediciNova) Short Percentage of Float


MNOV MediciNova Inc MNOV
33 GF Score
Price $1.33
! 2 Warning Signs
View Full Analysis

What is MediciNova Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MNOV vs ENTX, IMA, ACRV: Short Percentage of Float Comparison

For the Biotechnology subindustry, MediciNova's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MediciNova Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MediciNova's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where MediciNova's Short Percentage of Float falls into.


MNOV
33GF Score
MediciNova Inc MNOV
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MediciNova Business Description

Other Exchanges 4875:Japan
Address 4275 Executive Square, Suite 300, La Jolla, CA, USA, 92037
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
33GF Score

Get the complete analysis for MNOV

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.33
Price